Table of Content

1 INTRODUCTION 34
1.1 STUDY OBJECTIVES 34
1.2 MARKET DEFINITION 34
1.3 STUDY SCOPE 35
1.3.1 MARKETS COVERED & REGIONAL SCOPE 35
1.3.2 INCLUSIONS & EXCLUSIONS 36
1.3.3 YEARS CONSIDERED 36
1.4 CURRENCY CONSIDERED 37
1.5 STAKEHOLDERS 37
1.6 SUMMARY OF CHANGES 37
2 RESEARCH METHODOLOGY 39
2.1 RESEARCH DATA 39
2.1.1 SECONDARY DATA 40
2.1.2 PRIMARY DATA 40
2.2 MARKET ESTIMATION METHODOLOGY 42
2.2.1 MARKET ESTIMATION 42
2.2.2 INSIGHTS FROM PRIMARY EXPERTS 44
2.2.3 TOP-DOWN APPROACH 44
2.3 MARKET GROWTH RATE PROJECTIONS 46
2.4 DATA TRIANGULATION 48
2.5 RESEARCH ASSUMPTIONS 49
2.6 RESEARCH LIMITATIONS 50
2.7 RISK ANALYSIS 50
3 EXECUTIVE SUMMARY 51
4 PREMIUM INSIGHTS 56
4.1 VACCINE ADJUVANTS MARKET OVERVIEW 56
4.2 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT AND COUNTRY (2023) 57
4.3 VACCINE ADJUVANTS MARKET SHARE, BY VACCINE TYPE, 2024 VS. 2029 58
4.4 VACCINE ADJUVANTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 59
5 MARKET OVERVIEW 60
5.1 INTRODUCTION 60
5.2 MARKET DYNAMICS 60
5.2.1 DRIVERS 61
5.2.1.1 Rising demand for vaccines and expanding government immunization programs 61
5.2.1.2 Technological advancements and development of novel adjuvants 62
5.2.1.3 Increasing livestock production and rising incidence of animal diseases 62
5.2.1.4 Increased investments in research & development and high number of vaccine adjuvants under pipeline 63
5.2.2 RESTRAINTS 63
5.2.2.1 Cost implications of vaccine adjuvant development 63
5.2.2.2 Side effects and toxicity of adjuvants 64
5.2.3 OPPORTUNITIES 64
5.2.3.1 Personalized and combination vaccines 64
5.2.3.2 Increased investments in R&D of plant-based vaccines 65
5.2.3.3 Growth in companion animals market 65
5.2.4 CHALLENGES 65
5.2.4.1 Concerns regarding animal-sourced vaccine adjuvants 65
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 66
5.4 PRICING ANALYSIS 66
5.4.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER,
2022–2024 67
5.4.2 AVERAGE SELLING PRICE OF PRODUCTS, BY REGION, 2024 68
5.5 SUPPLY CHAIN ANALYSIS 69
5.6 VALUE CHAIN ANALYSIS 70
5.7 ECOSYSTEM ANALYSIS 72
5.7.1 VACCINE ADJUVANTS MARKET: RAW MATERIAL SUPPLIERS 73
5.7.2 VACCINE ADJUVANTS MARKET: PRODUCT MANUFACTURERS 73
5.7.3 VACCINE ADJUVANTS MARKET: END USERS 73
5.7.4 VACCINE ADJUVANTS MARKET: REGULATORY BODIES 74
5.8 TECHNOLOGY ANALYSIS 75
5.8.1 KEY TECHNOLOGIES 75
5.8.1.1 Toll-like receptor (TLR) agonists 75
5.8.1.2 Emulsion-based adjuvants 75
5.8.2 COMPLEMENTARY TECHNOLOGIES 76
5.8.2.1 Artificial intelligence (AI) and machine learning (ML) 76
5.8.3 ADJACENT TECHNOLOGIES 76
5.8.3.1 Nanotechnology in vaccine delivery 76
5.9 PATENT ANALYSIS 77
5.10 KEY CONFERENCES & EVENTS, 2024–2025 78
5.11 REGULATORY ANALYSIS 79
5.11.1 REGULATORY LANDSCAPE 79
5.11.1.1 North America 79
5.11.1.1.1 US 79
5.11.1.1.2 Canada 79
5.11.1.2 Europe 79
5.11.1.3 Asia Pacific 79
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
5.12 INVESTMENT & FUNDING SCENARIO 83
5.13 PORTER’S FIVE FORCES ANALYSIS 84
5.13.1 THREAT OF NEW ENTRANTS 85
5.13.2 THREAT OF SUBSTITUTES 85
5.13.3 BARGAINING POWER OF BUYERS 85
5.13.4 BARGAINING POWER OF SUPPLIERS 85
5.13.5 INTENSITY OF COMPETITIVE RIVALRY 85
5.14 KEY STAKEHOLDERS & BUYING CRITERIA 86
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 86
5.14.2 BUYING CRITERIA FOR END USERS 87
5.15 TRADE ANALYSIS 89
5.15.1 IMPORT DATA 89
5.15.2 EXPORT DATA 90
5.16 PIPELINE DATA FOR VACCINE ADJUVANTS 91
5.17 IMPACT OF AI/GENERATIVE AI ON VACCINE ADJUVANTS MARKET 92
6 VACCINE ADJUVANTS MARKET, BY PRODUCT 94
6.1 INTRODUCTION 95
6.2 EMULSION ADJUVANTS 95
6.2.1 EXTENSIVE USE OF EMULSION ADJUVANTS IN HUMAN VACCINES TO DRIVE GROWTH 95
6.3 PATHOGEN COMPONENTS 99
6.3.1 INCREASING NUMBER OF PROMINENT MARKET PLAYERS OFFERING BACTERIA-DERIVED ADJUVANTS TO DRIVE SEGMENTAL GROWTH 99
6.4 SAPONIN-BASED ADJUVANTS 103
6.4.1 INCREASING USE AND GROWING DEMAND FOR SAPONIN-BASED ADJUVANTS TO DRIVE MARKET GROWTH 103
6.5 PARTICULATE-BASED ADJUVANTS 107
6.5.1 GROWING POPULARITY OF MINERAL-BASED ADJUVANTS TO PROPEL MARKET 107
6.6 OTHER ADJUVANTS 111
7 VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE 116
7.1 INTRODUCTION 117
7.2 ORGANIC ADJUVANTS 117
7.2.1 GROWING DEMAND FOR VACCINES WITH HIGH EFFICACY TO BOOST MARKET 117
7.3 INORGANIC ADJUVANTS 121
7.3.1 INCREASING USE OF INORGANIC ADJUVANTS FOR VETERINARY VACCINE DEVELOPMENT TO SUPPORT MARKET GROWTH 121
?
8 VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION 126
8.1 INTRODUCTION 127
8.2 INTRAMUSCULAR 127
8.2.1 INTRAMUSCULAR ROUTE TO BE LARGEST AND FASTEST-GROWING MARKET SEGMENT DURING FORECAST PERIOD 127
8.3 SUBCUTANEOUS 131
8.3.1 WIDESPREAD USE OF SUBCUTANEOUS ROUTE OF ADMINISTRATION TO BOOST MARKET 131
8.4 OTHER ROUTES OF ADMINISTRATION 136
9 VACCINE ADJUVANTS MARKET, BY DISEASE TYPE 141
9.1 INTRODUCTION 142
9.2 INFECTIOUS DISEASES 142
9.2.1 INCREASED PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 142
9.3 CANCER 147
9.3.1 INCREASING DEMAND FOR NOVEL CANCER VACCINES TO SUPPORT MARKET GROWTH 147
9.4 OTHER DISEASES 151
10 VACCINE ADJUVANTS MARKET, BY APPLICATION 156
10.1 INTRODUCTION 157
10.2 RESEARCH APPLICATIONS 157
10.2.1 EXTENSIVE R&D FOR DEVELOPMENT OF VACCINE ADJUVANTS TO DRIVE MARKET 157
10.3 COMMERCIAL APPLICATIONS 161
10.3.1 GROWING USE OF VACCINE ADJUVANTS FOR COMMERCIAL APPLICATIONS TO SUPPORT MARKET GROWTH 161
11 VACCINE ADJUVANTS MARKET, BY VACCINE TYPE 166
11.1 INTRODUCTION 167
11.2 HUMAN VACCINES 167
11.2.1 INFECTIOUS DISEASES 171
11.2.1.1 Rising prevalence of infectious diseases to drive market growth 171
11.2.2 THERAPEUTIC 175
11.2.2.1 Rising investments in development of therapeutic vaccines to boost market 175
11.3 VETERINARY VACCINES 179
11.3.1 COMPANION ANIMALS 183
11.3.1.1 Increasing pet ownership and rising focus on pet health and wellness to play key role in driving market growth 183
11.3.2 LIVESTOCK ANIMALS 187
11.3.2.1 Increasing demand for high-quality meat, dairy, and other animal products to aid growth 187
11.3.3 OTHER ANIMALS 191
12 VACCINE ADJUVANTS MARKET, BY REGION 196
12.1 INTRODUCTION 197
12.2 NORTH AMERICA 197
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 198
12.2.2 US 203
12.2.2.1 US to dominate North American market during forecast period 203
12.2.3 CANADA 207
12.2.3.1 Increasing government funding for vaccine research to drive market growth in Canada 207
12.3 EUROPE 211
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 214
12.3.2 GERMANY 215
12.3.2.1 Increasing investments by various key players and growing funding from government organizations to drive market 215
12.3.3 UK 219
12.3.3.1 Rising investments in vaccine development to boost market growth 219
12.3.4 FRANCE 223
12.3.4.1 Focus on new vaccine development to drive market growth 223
12.3.5 ITALY 227
12.3.5.1 Government initiatives for vaccine development to boost market growth 227
12.3.6 SPAIN 231
12.3.6.1 Increasing investments in vaccine development by government and private organizations to support market growth in Spain 231
12.3.7 REST OF EUROPE 234
12.4 ASIA PACIFIC 238
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 243
12.4.2 CHINA 244
12.4.2.1 Government support & strategic initiatives by key players to strengthen biotechnology sector in China 244
12.4.3 JAPAN 248
12.4.3.1 Government initiatives for vaccines to boost market 248
12.4.4 INDIA 252
12.4.4.1 Growth of biotechnology sector and development of new vaccines to support market growth in India 252
12.4.5 SOUTH KOREA 256
12.4.5.1 Strategic collaborations to expand both human and veterinary vaccine sectors in South Korea 256
12.4.6 AUSTRALIA 260
12.4.6.1 Government support and strategic alliances to drive market 260
12.4.7 REST OF ASIA PACIFIC 264
?
12.5 LATIN AMERICA 267
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 271
12.5.2 BRAZIL 272
12.5.2.1 Robust healthcare infrastructure and thriving livestock industry to support market growth 272
12.5.3 MEXICO 276
12.5.3.1 Government commitment to immunization programs to fuel growth 276
12.5.4 ARGENTINA 279
12.5.4.1 Growing pharmaceutical sector to drive growth in Argentina 279
12.5.5 REST OF LATIN AMERICA 283
12.6 MIDDLE EAST 286
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 286
12.6.2 GCC COUNTRIES 291
12.6.2.1 Saudi Arabia 294
12.6.2.1.1 Strategic emphasis on advancing vaccine development for both human and veterinary applications to fuel growth 294
12.6.2.2 United Arab Emirates (UAE) 298
12.6.2.2.1 Increasing focus on developing cutting-edge vaccine technologies to contribute to market growth 298
12.6.2.3 Rest of GCC countries 302
12.6.3 REST OF MIDDLE EAST 305
12.7 AFRICA 309
12.7.1 INCREASING INVESTMENTS IN VACCINE PRODUCTION FACILITIES TO SUPPORT MARKET GROWTH 309
12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 309
13 COMPETITIVE LANDSCAPE 313
13.1 OVERVIEW 313
13.2 KEY PLAYER STRATEGY/RIGHT TO WIN, 2023 313
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN VACCINE ADJUVANTS MARKET 314
13.3 REVENUE ANALYSIS, 2019–2023 315
13.4 MARKET SHARE ANALYSIS, 2023 316
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 318
13.5.1 STARS 319
13.5.2 EMERGING LEADERS 319
13.5.3 PERVASIVE PLAYERS 319
13.5.4 PARTICIPANTS 319
13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 321
13.5.5.1 Company footprint 321
13.5.5.2 Product footprint 322
13.5.5.3 Application footprint 323
13.5.5.4 Region footprint 324
?
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 325
13.6.1 PROGRESSIVE COMPANIES 325
13.6.2 RESPONSIVE COMPANIES 325
13.6.3 DYNAMIC COMPANIES 325
13.6.4 STARTING BLOCKS 325
13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 327
13.7 COMPANY VALUATION & FINANCIAL METRICS 328
13.7.1 FINANCIAL METRICS 328
13.7.2 COMPANY VALUATION 329
13.8 BRAND/PRODUCT COMPARISON 330
13.9 COMPETITIVE SCENARIO 331
13.9.1 PRODUCT LAUNCHES & APPROVALS 331
13.9.2 DEALS 331
13.9.3 EXPANSIONS 332
14 COMPANY PROFILES 333
14.1 KEY PLAYERS 333
14.1.1 GSK PLC 333
14.1.1.1 Business overview 333
14.1.1.2 Products offered 334
14.1.1.3 Recent developments 335
14.1.1.3.1 Deals 335
14.1.1.4 MnM view 335
14.1.1.4.1 Key strengths 335
14.1.1.4.2 Strategic choices 335
14.1.1.4.3 Weaknesses & competitive threats 336
14.1.2 SEPPIC (A SUBSIDIARY OF AIR LIQUIDE GROUP) 337
14.1.2.1 Business overview 337
14.1.2.2 Products offered 338
14.1.2.3 Recent developments 339
14.1.2.3.1 Product launches 339
14.1.2.4 MnM view 340
14.1.2.4.1 Key strengths 340
14.1.2.4.2 Strategic choices 340
14.1.2.4.3 Weaknesses & competitive threats 340
14.1.3 CRODA INTERNATIONAL PLC 341
14.1.3.1 Business overview 341
14.1.3.2 Products offered 342
14.1.3.3 Recent developments 344
14.1.3.3.1 Deals 344
14.1.3.3.2 Expansions 345
?
14.1.3.4 MnM view 345
14.1.3.4.1 Key strengths 345
14.1.3.4.2 Strategic choices 345
14.1.3.4.3 Weaknesses & competitive threats 345
14.1.4 PHIBRO ANIMAL HEALTH CORPORATION 346
14.1.4.1 Business overview 346
14.1.4.2 Products offered 347
14.1.4.3 MnM view 348
14.1.4.3.1 Key strengths 348
14.1.4.3.2 Strategic choices 348
14.1.4.3.3 Weaknesses & competitive threats 348
14.1.5 SPI PHARMA (A SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC) 349
14.1.5.1 Business overview 349
14.1.5.2 Products offered 351
14.1.5.3 MnM view 352
14.1.5.3.1 Key strengths 352
14.1.5.3.2 Strategic choices 352
14.1.5.3.3 Weaknesses & competitive threats 352
14.1.6 AGENUS INC. 353
14.1.6.1 Business overview 353
14.1.6.2 Products offered 354
14.1.6.3 Recent developments 354
14.1.6.3.1 Deals 354
14.1.7 NOVAVAX 355
14.1.7.1 Business overview 355
14.1.7.2 Products offered 356
14.1.8 AURORIUM (FORMERLY VERTELLUS) 357
14.1.8.1 Business overview 357
14.1.8.2 Products offered 357
14.1.8.3 Recent developments 358
14.1.8.3.1 Deals 358
14.1.9 DYNAVAX TECHNOLOGIES CORPORATION 359
14.1.9.1 Business overview 359
14.1.9.2 Products offered 360
14.1.9.3 Recent developments 361
14.1.9.3.1 Deals 361
14.1.10 MERCK KGAA 362
14.1.10.1 Business overview 362
14.1.10.2 Products offered 363
14.1.11 VAXINE PTY LTD. 364
14.1.11.1 Business overview 364
14.1.11.2 Products offered 364
14.1.12 HAWAII BIOTECH INC. 365
14.1.12.1 Business overview 365
14.1.12.2 Products offered 365
14.1.13 CSL LIMITED 366
14.1.13.1 Business overview 366
14.1.13.2 Products offered 367
14.1.14 OZ BIOSCIENCES 368
14.1.14.1 Business overview 368
14.1.14.2 Products offered 368
14.1.15 INVIVOGEN 370
14.1.15.1 Business overview 370
14.1.15.2 Products offered 371
14.2 OTHER PLAYERS 372
14.2.1 ALLERGY THERAPEUTICS 372
14.2.2 EUBIOLOGICS CO., LTD. 373
14.2.3 PACIFIC GENETECH LIMITED 374
14.2.4 RIBOXX GMBH 375
14.2.5 CAPTIVATE PHARMACEUTICALS LLC 376
14.2.6 CREATIVE DIAGNOSTICS 377
14.2.7 LITEVAX B.V. 378
14.2.8 MUKTA INDUSTRIES 379
14.2.9 ONCOVIR, INC. 380
14.2.10 TITERMAX USA, INC. 381
15 APPENDIX 382
15.1 DISCUSSION GUIDE 382
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 385
15.3 CUSTOMIZATION OPTIONS 387
15.4 RELATED REPORTS 387
15.5 AUTHOR DETAILS 388



List of Figures

FIGURE 1 VACCINE ADJUVANTS MARKET SEGMENTATION & REGIONAL SCOPE 35
FIGURE 2 RESEARCH DESIGN 39
FIGURE 3 VACCINE ADJUVANTS MARKET: BREAKDOWN OF PRIMARIES 41
FIGURE 4 VACCINE ADJUVANTS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023 42
FIGURE 5 GLOBAL MARKET SIZE ESTIMATION APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023 43
FIGURE 6 ILLUSTRATIVE EXAMPLE OF GSK PLC: REVENUE SHARE ANALYSIS (2023) 43
FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 44
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 44
FIGURE 9 VACCINE ADJUVANTS MARKET: CAGR PROJECTIONS 46
FIGURE 10 DATA TRIANGULATION METHODOLOGY 48
FIGURE 11 VACCINE ADJUVANTS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION) 51
FIGURE 12 VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2024 VS. 2029 (USD MILLION) 52
FIGURE 13 VACCINE ADJUVANTS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION) 53
FIGURE 14 VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2024 VS. 2029 (USD MILLION) 54
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF VACCINE ADJUVANTS MARKET 55
FIGURE 16 ADVANCEMENTS IN VACCINE ADJUVANTS AND RISING DEMAND FOR BIO-BASED PRODUCTS TO DRIVE MARKET GROWTH 56
FIGURE 17 ADJUVANT EMULSIONS SEGMENT ACCOUNTED FOR LARGEST
MARKET SHARE IN 2023 57
FIGURE 18 HUMAN VACCINES TO DOMINATE MARKET DURING FORECAST PERIOD 58
FIGURE 19 CHINA PROJECTED TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 59
FIGURE 20 VACCINE ADJUVANTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 60
FIGURE 21 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES IN VACCINE ADJUVANTS MARKET 66
FIGURE 22 VACCINE ADJUVANTS MARKET: SUPPLY CHAIN ANALYSIS 69
FIGURE 23 VACCINE ADJUVANTS MARKET: VALUE CHAIN ANALYSIS 71
FIGURE 24 VACCINE ADJUVANTS MARKET: ECOSYSTEM ANALYSIS 72
FIGURE 25 NUMBER OF PATENTS APPLICATIONS/GRANTED, 2014?2024 77
FIGURE 26 VACCINE ADJUVANTS MARKET: PORTER’S FIVE FORCES ANALYSIS 84
FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VACCINE ADJUVANT PRODUCTS 86
FIGURE 28 KEY BUYING CRITERIA FOR VACCINE ADJUVANT PRODUCTS AMONG END USERS 87
FIGURE 29 VACCINE ADJUVANTS PIPELINE, BY PHASE 91
FIGURE 30 VACCINE ADJUVANTS MARKET: IMPACT OF AI 93
FIGURE 31 NORTH AMERICA: VACCINE ADJUVANTS MARKET SNAPSHOT 199
FIGURE 32 ASIA PACIFIC: VACCINE ADJUVANTS MARKET SNAPSHOT 239
FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS IN VACCINE ADJUVANTS MARKET 2019–2023 315
FIGURE 34 MARKET SHARE ANALYSIS OF KEY PLAYERS IN VACCINE ADJUVANTS MARKET (2023) 317
FIGURE 35 VACCINE ADJUVANTS MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2023 320
FIGURE 36 VACCINE ADJUVANTS MARKET: COMPANY FOOTPRINT 321
FIGURE 37 VACCINE ADJUVANTS MARKET: COMPANY EVALUATION MATRIX
(STARTUPS/SMES), 2023 326
FIGURE 38 EV/EBITDA OF KEY VENDORS 328
FIGURE 39 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 329
FIGURE 40 VACCINE ADJUVANTS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 330
FIGURE 41 GSK PLC: COMPANY SNAPSHOT (2023) 334
FIGURE 42 SEPPIC (A SUBSIDIARY OF AIR LIQUIDE GROUP): COMPANY SNAPSHOT (2023) 338
FIGURE 43 CRODA INTERNATIONAL PLC: COMPANY SNAPSHOT (2023) 342
FIGURE 44 PHIBRO ANIMAL HEALTH CORPORATION: COMPANY SNAPSHOT (2023) 347
FIGURE 45 SPI PHARMA (A SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC):
COMPANY SNAPSHOT (2023) 350
FIGURE 46 AGENUS INC.: COMPANY SNAPSHOT (2023) 353
FIGURE 47 NOVAVAX: COMPANY SNAPSHOT (2023) 355
FIGURE 48 DYNAVAX TECHNOLOGIES CORPORATION: COMPANY SNAPSHOT (2023) 360
FIGURE 49 MERCK KGAA: COMPANY SNAPSHOT (2023) 363
FIGURE 50 CSL LIMITED: COMPANY SNAPSHOT (2023) 367

List of Tables

TABLE 1 VACCINE ADJUVANTS MARKET: INCLUSIONS & EXCLUSIONS 36
TABLE 2 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 47
TABLE 3 VACCINE ADJUVANTS MARKET: RISK ASSESSMENT ANALYSIS 50
TABLE 4 GLOBAL DIPHTHERIA TETANUS TOXOID AND PERTUSSIS (DTP) VACCINATION COVERAGE, 2019–2023 61
TABLE 5 GLOBAL BACILLUS CALMETTE–GU?RIN (BCG) VACCINATION COVERAGE 2019–2023 61
TABLE 6 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022–2024 67
TABLE 7 AVERAGE SELLING PRICE OF PRODUCT, BY REGION, 2024 68
TABLE 8 VACCINE ADJUVANTS MARKET: RAW MATERIAL SUPPLIERS 73
TABLE 9 VACCINE ADJUVANTS MARKET: PRODUCT MANUFACTURERS 73
TABLE 10 VACCINE ADJUVANTS MARKET: END USERS 74
TABLE 11 VACCINE ADJUVANTS MARKET: REGULATORY BODIES 74
TABLE 12 KEY PATENTS IN VACCINE ADJUVANTS MARKET 78
TABLE 13 VACCINE ADJUVANTS MARKET: KEY CONFERENCES & EVENTS, 2024–2025 78
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81
TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83
TABLE 19 VACCINE ADJUVANTS MARKET: PORTER’S FIVE FORCES ANALYSIS 84
TABLE 20 KEY BUYING CRITERIA FOR VACCINE ADJUVANT PRODUCTS, BY END USER 87
TABLE 21 IMPORT DATA FOR VACCINE ADJUVANTS 89
TABLE 22 EXPORT DATA FOR VACCINE ADJUVANTS 90
TABLE 23 PIPELINE STUDIES FOR VACCINE ADJUVANTS, PHASE 3 AND PHASE 2|PHASE3 91
TABLE 24 VACCINE ADJUVANTS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 95
TABLE 25 EMULSION ADJUVANTS MARKET, BY REGION, 2022–2029 (USD MILLION) 96
TABLE 26 NORTH AMERICA: EMULSION ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 97
TABLE 27 EUROPE: EMULSION ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 97
TABLE 28 ASIA PACIFIC: EMULSION ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 98
TABLE 29 LATIN AMERICA: EMULSION ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 98
TABLE 30 MIDDLE EAST: EMULSION ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 99
TABLE 31 GCC COUNTRIES: EMULSION ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 99
TABLE 32 PATHOGEN COMPONENTS MARKET, BY REGION, 2022–2029 (USD MILLION) 100
TABLE 33 NORTH AMERICA: PATHOGEN COMPONENTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 101
TABLE 34 EUROPE: PATHOGEN COMPONENTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 101
TABLE 35 ASIA PACIFIC: PATHOGEN COMPONENTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 102
TABLE 36 LATIN AMERICA: PATHOGEN COMPONENTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 102
TABLE 37 MIDDLE EAST: PATHOGEN COMPONENTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 103
TABLE 38 GCC COUNTRIES: PATHOGEN COMPONENTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 103
TABLE 39 SAPONIN-BASED ADJUVANTS MARKET, BY REGION, 2022–2029 (USD MILLION) 104
TABLE 40 NORTH AMERICA: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 105
TABLE 41 EUROPE: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 105
TABLE 42 ASIA PACIFIC: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 106
TABLE 43 LATIN AMERICA: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 106
TABLE 44 MIDDLE EAST: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 107
TABLE 45 GCC COUNTRIES: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 107
TABLE 46 PARTICULATE-BASED ADJUVANTS MARKET, BY REGION 2022–2029 (USD MILLION) 108
TABLE 47 NORTH AMERICA: PARTICULATE-BASED ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 109
TABLE 48 EUROPE: PARTICULATE-BASED ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 109
TABLE 49 ASIA PACIFIC: PARTICULATE-BASED ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 110
TABLE 50 LATIN AMERICA: PARTICULATE-BASED ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 110
TABLE 51 MIDDLE EAST: PARTICULATE-BASED ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 111
TABLE 52 GCC COUNTRIES: PARTICULATE-BASED ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 111
TABLE 53 OTHER ADJUVANTS MARKET, BY REGION, 2022–2029 (USD MILLION) 112
TABLE 54 NORTH AMERICA: OTHER ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 113
TABLE 55 EUROPE: OTHER ADJUVANTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 56 ASIA PACIFIC: OTHER ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 114
TABLE 57 LATIN AMERICA: OTHER ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 114
TABLE 58 MIDDLE EAST: OTHER ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 115
TABLE 59 GCC COUNTRIES: OTHER ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 115
TABLE 60 VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE, 2022–2029 (USD MILLION) 117
TABLE 61 ORGANIC VACCINE ADJUVANTS MARKET, BY REGION, 2022–2029 (USD MILLION) 118
TABLE 62 NORTH AMERICA: ORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 118
TABLE 63 EUROPE: ORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 119
TABLE 64 ASIA PACIFIC: ORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 119
TABLE 65 LATIN AMERICA: ORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 120
TABLE 66 MIDDLE EAST: ORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 120
TABLE 67 GCC COUNTRIES: ORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 121
TABLE 68 INORGANIC VACCINE ADJUVANTS MARKET, BY REGION 2022–2029 (USD MILLION) 122
TABLE 69 NORTH AMERICA: INORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 122
TABLE 70 EUROPE: INORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 123
TABLE 71 ASIA PACIFIC: INORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 123
TABLE 72 LATIN AMERICA: INORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 124
TABLE 73 MIDDLE EAST: INORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 124
TABLE 74 GCC COUNTRIES: INORGANIC VACCINE ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 125
TABLE 75 VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION 2022–2029 (USD MILLION) 127
TABLE 76 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR ADMINISTRATION 128
TABLE 77 VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION BY REGION, 2022–2029 (USD MILLION) 128
TABLE 78 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 79 EUROPE: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 80 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 130
TABLE 81 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 130
TABLE 82 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 131
TABLE 83 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 131
TABLE 84 ADVANTAGES AND DISADVANTAGES OF SUBCUTANEOUS ADMINISTRATION 132
TABLE 85 VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION BY REGION, 2022–2029 (USD MILLION) 133
TABLE 86 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 87 EUROPE: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 134
TABLE 88 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 134
TABLE 89 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 135
TABLE 90 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 135
TABLE 91 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 136
TABLE 92 VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION BY REGION, 2022–2029 (USD MILLION) 137
TABLE 93 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 94 EUROPE: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 138
TABLE 95 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 138
TABLE 96 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 139
TABLE 97 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 139
TABLE 98 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 140
TABLE 99 VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022–2029 (USD MILLION) 142
TABLE 100 GLOBAL IMMUNIZATION COVERAGE, BY VACCINE, 2020–2023 (%) 143
TABLE 101 VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY REGION 2022–2029 (USD MILLION) 144
TABLE 102 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES BY COUNTRY, 2022–2029 (USD MILLION) 144
TABLE 103 EUROPE: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 104 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 105 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES BY COUNTRY, 2022–2029 (USD MILLION) 146
TABLE 106 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES BY COUNTRY, 2022–2029 (USD MILLION) 146
TABLE 107 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES BY COUNTRY, 2022–2029 (USD MILLION) 147
TABLE 108 VACCINE ADJUVANTS MARKET FOR CANCER, BY REGION 2022–2029 (USD MILLION) 148
TABLE 109 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 148
TABLE 110 EUROPE: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY 2022–2029 (USD MILLION) 149
TABLE 111 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY 2022–2029 (USD MILLION) 149
TABLE 112 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY 2022–2029 (USD MILLION) 150
TABLE 113 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY 2022–2029 (USD MILLION) 150
TABLE 114 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 151
TABLE 115 VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY REGION 2022–2029 (USD MILLION) 152
TABLE 116 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES BY COUNTRY, 2022–2029 (USD MILLION) 152
TABLE 117 EUROPE: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 153
TABLE 118 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 153
TABLE 119 LATIN AMERICA: VACCINE ADJUVANTS MARKET OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 154
TABLE 120 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 154
TABLE 121 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES BY COUNTRY, 2022–2029 (USD MILLION) 155
TABLE 122 VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 157
TABLE 123 VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY REGION 2022–2029 (USD MILLION) 158
TABLE 124 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 158
TABLE 125 EUROPE: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS BY COUNTRY, 2022–2029 (USD MILLION) 159
TABLE 126 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS BY COUNTRY, 2022–2029 (USD MILLION) 159
TABLE 127 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS BY COUNTRY, 2022–2029 (USD MILLION) 160
TABLE 128 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS BY COUNTRY, 2022–2029 (USD MILLION) 160
TABLE 129 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 161
TABLE 130 VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY REGION, 2022–2029 (USD MILLION) 162
TABLE 131 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 162
TABLE 132 EUROPE: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS BY COUNTRY, 2022–2029 (USD MILLION) 163
TABLE 133 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS BY COUNTRY, 2022–2029 (USD MILLION) 163
TABLE 134 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 164
TABLE 135 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 164
TABLE 136 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 165
TABLE 137 VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022–2029 (USD MILLION) 167
TABLE 138 VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION 2022–2029 (USD MILLION) 168
TABLE 139 VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY REGION 2022–2029 (USD MILLION) 168
TABLE 140 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES BY COUNTRY, 2022–2029 (USD MILLION) 169
TABLE 141 EUROPE: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY COUNTRY, 2022–2029 (USD MILLION) 169
TABLE 142 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY COUNTRY, 2022–2029 (USD MILLION) 170
TABLE 143 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES BY COUNTRY, 2022–2029 (USD MILLION) 170
TABLE 144 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES BY COUNTRY, 2022–2029 (USD MILLION) 171
TABLE 145 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES BY COUNTRY, 2022–2029 (USD MILLION) 171
TABLE 146 VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASE APPLICATIONS BY REGION, 2022–2029 (USD MILLION) 172
TABLE 147 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASE APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 172
TABLE 148 EUROPE: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASE APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 173
TABLE 149 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASE APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 173
TABLE 150 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASE APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 174
TABLE 151 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASE APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 174
TABLE 152 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASE APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 175
TABLE 153 VACCINE ADJUVANTS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2022–2029 (USD MILLION) 176
TABLE 154 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 176
TABLE 155 EUROPE: VACCINE ADJUVANTS MARKET FOR THERAPEUTIC APPLICATIONS BY COUNTRY, 2022–2029 (USD MILLION) 177
TABLE 156 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR THERAPEUTIC APPLICATIONS BY COUNTRY, 2022–2029 (USD MILLION) 177
TABLE 157 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 178
TABLE 158 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 178
TABLE 159 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 179
TABLE 160 VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 180
TABLE 161 VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY REGION 2022–2029 (USD MILLION) 180
TABLE 162 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES BY COUNTRY, 2022–2029 (USD MILLION) 181
TABLE 163 EUROPE: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY COUNTRY, 2022–2029 (USD MILLION) 181
TABLE 164 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES BY COUNTRY, 2022–2029 (USD MILLION) 182
TABLE 165 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES BY COUNTRY, 2022–2029 (USD MILLION) 182
TABLE 166 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES BY COUNTRY, 2022–2029 (USD MILLION) 183
TABLE 167 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES BY COUNTRY, 2022–2029 (USD MILLION) 183
TABLE 168 VACCINE ADJUVANTS MARKET FOR COMPANION ANIMALS, BY REGION 2022–2029 (USD MILLION) 184
TABLE 169 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR COMPANION ANIMALS BY COUNTRY, 2022–2029 (USD MILLION) 184
TABLE 170 EUROPE: VACCINE ADJUVANTS MARKET FOR COMPANION ANIMALS, BY COUNTRY, 2022–2029 (USD MILLION) 185
TABLE 171 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR COMPANION ANIMALS BY COUNTRY, 2022–2029 (USD MILLION) 185
TABLE 172 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR COMPANION ANIMALS BY COUNTRY, 2022–2029 (USD MILLION) 186
TABLE 173 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR COMPANION ANIMALS BY COUNTRY, 2022–2029 (USD MILLION) 186
TABLE 174 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR COMPANION ANIMALS, BY COUNTRY, 2022–2029 (USD MILLION) 187
TABLE 175 VACCINE ADJUVANTS MARKET FOR LIVESTOCK ANIMALS, BY REGION 2022–2029 (USD MILLION) 188
TABLE 176 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR LIVESTOCK ANIMALS BY COUNTRY, 2022–2029 (USD MILLION) 188
TABLE 177 EUROPE: VACCINE ADJUVANTS MARKET FOR LIVESTOCK ANIMALS, BY COUNTRY, 2022–2029 (USD MILLION) 189
TABLE 178 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR LIVESTOCK ANIMALS BY COUNTRY, 2022–2029 (USD MILLION) 189
TABLE 179 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR LIVESTOCK ANIMALS BY COUNTRY, 2022–2029 (USD MILLION) 190
TABLE 180 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR LIVESTOCK ANIMALS BY COUNTRY, 2022–2029 (USD MILLION) 190
TABLE 181 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR LIVESTOCK ANIMALS BY COUNTRY, 2022–2029 (USD MILLION) 191
TABLE 182 VACCINE ADJUVANTS MARKET FOR OTHER ANIMALS, BY REGION 2022–2029 (USD MILLION) 192
TABLE 183 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR OTHER ANIMALS BY COUNTRY, 2022–2029 (USD MILLION) 192
TABLE 184 EUROPE: VACCINE ADJUVANTS MARKET FOR OTHER ANIMALS, BY COUNTRY, 2022–2029 (USD MILLION) 193
TABLE 185 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR OTHER ANIMALS, BY COUNTRY, 2022–2029 (USD MILLION) 193
TABLE 186 LATIN AMERICA: VACCINE ADJUVANTS MARKET FOR OTHER ANIMALS BY COUNTRY, 2022–2029 (USD MILLION) 194
TABLE 187 MIDDLE EAST: VACCINE ADJUVANTS MARKET FOR OTHER ANIMALS, BY COUNTRY, 2022–2029 (USD MILLION) 194
TABLE 188 GCC COUNTRIES: VACCINE ADJUVANTS MARKET FOR OTHER ANIMALS BY COUNTRY, 2022–2029 (USD MILLION) 195
TABLE 189 VACCINE ADJUVANTS MARKET, BY REGION, 2022–2029 (USD MILLION) 197
TABLE 190 NORTH AMERICA: KEY MACROINDICATORS 198
TABLE 191 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY COUNTRY 2022–2029 (USD MILLION) 200
TABLE 192 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE 2022–2029 (USD MILLION) 200
TABLE 193 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE 2022–2029 (USD MILLION) 201
TABLE 194 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 201
TABLE 195 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION 2022–2029 (USD MILLION) 201
TABLE 196 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE 2022–2029 (USD MILLION) 202
TABLE 197 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE 2022–2029 (USD MILLION) 202
TABLE 198 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES BY APPLICATION, 2022–2029 (USD MILLION) 202
TABLE 199 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES BY ANIMAL TYPE, 2022–2029 (USD MILLION) 203
TABLE 200 US: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 204
TABLE 201 US: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE 2022–2029 (USD MILLION) 204
TABLE 202 US: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION 2022–2029 (USD MILLION) 205
TABLE 203 US: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 205
TABLE 204 US: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022–2029 (USD MILLION) 205
TABLE 205 US: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022–2029 (USD MILLION) 206
TABLE 206 US: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022–2029 (USD MILLION) 206
TABLE 207 US: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 206
TABLE 208 CANADA: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE 2022–2029 (USD MILLION) 208
TABLE 209 CANADA: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE 2022–2029 (USD MILLION) 208
TABLE 210 CANADA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION 2022–2029 (USD MILLION) 209
TABLE 211 CANADA: VACCINE ADJUVANTS MARKET, BY APPLICATION 2022–2029 (USD MILLION) 209
TABLE 212 CANADA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE 2022–2029 (USD MILLION) 209
TABLE 213 CANADA: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE 2022–2029 (USD MILLION) 210
TABLE 214 CANADA: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022–2029 (USD MILLION) 210
TABLE 215 CANADA: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 210
TABLE 216 EUROPE: VACCINE ADJUVANTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 211
TABLE 217 EUROPE: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE 2022–2029 (USD MILLION) 211
TABLE 218 EUROPE: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE 2022–2029 (USD MILLION) 212
TABLE 219 EUROPE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION 2022–2029 (USD MILLION) 212
TABLE 220 EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION 2022–2029 (USD MILLION) 212
TABLE 221 EUROPE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE 2022–2029 (USD MILLION) 213
TABLE 222 EUROPE: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE 2022–2029 (USD MILLION) 213
TABLE 223 EUROPE: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022–2029 (USD MILLION) 213
TABLE 224 EUROPE: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 214
TABLE 225 EUROPE: KEY MACROINDICATORS 215
TABLE 226 GERMANY: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE 2022–2029 (USD MILLION) 216
TABLE 227 GERMANY: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE 2022–2029 (USD MILLION) 216
TABLE 228 GERMANY: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION 2022–2029 (USD MILLION) 217
TABLE 229 GERMANY: VACCINE ADJUVANTS MARKET, BY APPLICATION 2022–2029 (USD MILLION) 217
TABLE 230 GERMANY: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE 2022–2029 (USD MILLION) 217
TABLE 231 GERMANY: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE 2022–2029 (USD MILLION) 218
TABLE 232 GERMANY: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES BY APPLICATION, 2022–2029 (USD MILLION) 218
TABLE 233 GERMANY: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 218
TABLE 234 UK: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE 2022–2029 (USD MILLION) 220
TABLE 235 UK: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE 2022–2029 (USD MILLION) 220
TABLE 236 UK: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION 2022–2029 (USD MILLION) 221
TABLE 237 UK: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 221
TABLE 238 UK: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022–2029 (USD MILLION) 221
TABLE 239 UK: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE, 2022–2029 (USD MILLION) 222
TABLE 240 UK: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022–2029 (USD MILLION) 222
TABLE 241 UK: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 222
TABLE 242 FRANCE: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE 2022–2029 (USD MILLION) 224
TABLE 243 FRANCE: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE 2022–2029 (USD MILLION) 224
TABLE 244 FRANCE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION 2022–2029 (USD MILLION) 225
TABLE 245 FRANCE: VACCINE ADJUVANTS MARKET, BY APPLICATION 2022–2029 (USD MILLION) 225
TABLE 246 FRANCE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE 2022–2029 (USD MILLION) 225
TABLE 247 FRANCE: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE 2022–2029 (USD MILLION) 226
TABLE 248 FRANCE: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022–2029 (USD MILLION) 226
TABLE 249 FRANCE: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 226
TABLE 250 ITALY: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE 2022–2029 (USD MILLION) 228
TABLE 251 ITALY: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE 2022–2029 (USD MILLION) 228
TABLE 252 ITALY: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION 2022–2029 (USD MILLION) 229
TABLE 253 ITALY: VACCINE ADJUVANTS MARKET, BY APPLICATION 2022–2029 (USD MILLION) 229
TABLE 254 ITALY: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE 2022–2029 (USD MILLION) 229
TABLE 255 ITALY: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE 2022–2029 (USD MILLION) 230
TABLE 256 ITALY: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022–2029 (USD MILLION) 230
TABLE 257 ITALY: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 230
TABLE 258 SPAIN: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE 2022–2029 (USD MILLION) 231
TABLE 259 SPAIN: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE 2022–2029 (USD MILLION) 232
TABLE 260 SPAIN: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION 2022–2029 (USD MILLION) 232
TABLE 261 SPAIN: VACCINE ADJUVANTS MARKET, BY APPLICATION 2022–2029 (USD MILLION) 232
TABLE 262 SPAIN: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE 2022–2029 (USD MILLION) 233
TABLE 263 SPAIN: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE 2022–2029 (USD MILLION) 233
TABLE 264 SPAIN: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES, BY APPLICATION, 2022–2029 (USD MILLION) 233
TABLE 265 SPAIN: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 234
TABLE 266 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE 2022–2029 (USD MILLION) 235
TABLE 267 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE 2022–2029 (USD MILLION) 235
TABLE 268 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 236
TABLE 269 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION 2022–2029 (USD MILLION) 236
TABLE 270 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE 2022–2029 (USD MILLION) 237
TABLE 271 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY VACCINE TYPE 2022–2029 (USD MILLION) 237
TABLE 272 REST OF EUROPE: VACCINE ADJUVANTS MARKET FOR HUMAN VACCINES BY APPLICATION, 2022–2029 (USD MILLION) 237
TABLE 273 REST OF EUROPE: VACCINE ADJUVANTS MARKET FOR VETERINARY VACCINES BY ANIMAL TYPE, 2022–2029 (USD MILLION) 238